Sept. 19, 2019 06:38 UTC
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- The SanBio Group (SanBio Co., Ltd. and SanBio, Inc.)(TOKYO:4592), a scientific leader in regenerative medicine for neurological disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) Designation for SB623 cell therapy for the treatment of chronic neurological motor deficits secondary to traumatic brain injury (TBI). The designation is based on clinical results of SB623 including the Phase 2 Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) trial.
Created under the 21st Century Cures Act, the RMAT designation is reserved for a regenerative medicine therapy intended to treat, modify, reverse, or cure a serious condition, and clinical evidence indicates that the therapy has the potential to address unmet medical needs for such disease or condition. Similar to the Breakthrough Therapy designation, the RMAT designation offers sponsors of cell and gene therapies eligibility for expedited development and regulatory review of their product candidate, including earlier and more frequent consultation with the FDA, and the potential for Priority Review and Accelerated Approval.
The RMAT designation for SB623 is an important regulatory milestone for SanBio as we investigate it as a treatment option for patients with chronic neurological motor deficits resulting from a traumatic brain injury, said Bijan Nejadnik, M.D., Chief Medical Officer and Head of Research. TBIs are one of the most common health conditions worldwide that often cause long-term complications or death. We look forward to working with the FDA on a potentially accelerated clinical development program to address this serious unmet medical need.
The RMAT designation augments the Sakigake Designation for innovative medical products from the Ministry of Health, Labour, and Welfare of Japan.
About SB623 SB623 is a proprietary, cell-based investigational product made from modified and cultured adult bone marrow-derived mesenchymal stem cells that undergo temporary genetic modification. Implantation of SB623 cells into injured nerve tissue in the brain is expected to trigger the brains natural regenerative ability to recover lost motor functions.
SanBio expects to initiate a Phase 3 trial for SB623 for the treatment of chronic neurological motor deficits secondary to TBI by the end of the fiscal year ending January 31, 2021. SB623 is also currently in a Phase 2b clinical trial for treatment of chronic motor deficit resulting from ischemic stroke.
About the Study of Modified Stem Cells in Traumatic Brain Injury (STEMTRA) Trial STEMTRA was a 12-month, Phase 2, randomized, double-blind, surgical sham-controlled, global trial evaluating the efficacy and safety of SB623 compared to sham surgery in patients with stable chronic neurological motor deficits secondary to TBI. In this study, SB623 cells were implanted directly around the site of brain injury.
To be eligible for this trial, patients (ages 18-75) must have been at least 12 months post-TBI and had a Glasgow Outcome Scale extended (GOS-E) score of 3-6 (e.g., moderate or severe disability). Patients must also have been able to undergo all planned neurological assessments and had no seizures in the prior three months. The primary endpoint was mean change from baseline in Fugl-Meyer Motor Scale (FMMS) score which measures changes in motor impairment at six months. The STEMTRA trial enrolled 61 patients from 13 surgical and 18 assessment sites in the U.S., Japan and Ukraine.
In this study, SB623 met its primary endpoint, with patients treated with SB623 achieving an average 8.3 point improvement from baseline in the FMMS, versus 2.3 in the control group, at 24 weeks (p=0.040). Of patients treated with SB623, 18 (39.1%) reached a 10 or more point improvement of FMMS compared to one control patient (6.7%; p=0.039). No new safety signals were identified. The most commonly reported adverse event were headaches.
About SanBio Group (SanBio Co., Ltd. and SanBio, Inc.) SanBio Group is a regenerative medicine company with cell-based products focused on neurological disorders in various stages of research, development and clinical trials. The Companys lead asset, SB623, is currently being investigated for the treatment of several conditions including chronic neurological motor deficit resulting from ischemic stroke and traumatic brain injury. SanBio has received a Japanese marketing license for regenerative medicine products from the Tokyo Metropolitan Government, and plans to begin marketing regenerative medicine products in Japan by the end of the fiscal year ending January 31, 2021. The Company is headquartered in Tokyo, Japan and Mountain View, California, and additional information about SanBio Group is available at https://sanbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190918006094/en/
- Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press - December 6th, 2019
- Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description - December 6th, 2019
- Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast... - December 6th, 2019
- Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal - December 5th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates - December 5th, 2019
- Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24 - December 5th, 2019
- Stem Cell Market 2019 | What Will Be the Market Size and the Growth Rate Analysis by 2026? - Hitz Dairies - December 3rd, 2019
- Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash - December 3rd, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - BioSpace - November 28th, 2019
- Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times - November 28th, 2019
- Canine Stem Cell Therapy Market Value Projected to Expand by 2026 - The Hilltop Monitor - November 28th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News Info - November 28th, 2019
- Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger - November 28th, 2019
- Lulu and Nana are the result of a defiant experiment in human gene modification - The Irish Times - November 28th, 2019
- Types of Adult Stem Cells - Stem Cell Institute - November 26th, 2019
- Adult Leukemia: What You Need to Know - Dana-Farber Cancer Institute - November 26th, 2019
- Hatching disease in a dish: The new frontier in drug testing - Maclean's - November 26th, 2019
- Bedfordshire Police officer reunited with woman whose life he saved through stem cell donation - Bedford Today - November 26th, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - GlobeNewswire - November 26th, 2019
- Bedfordshire Police officer reunited with stem cell recipient - Cranfield and Marston Vale Chronicle - November 26th, 2019
- Keeping cells alive | Interviews - The Naked Scientists - November 26th, 2019
- Dana-Farber joins with leading Boston teaching hospitals and universities - Mirage News - November 26th, 2019
- Applying AI and CRISPR to stem cells to improve regenerative medicine - FierceBiotech - November 20th, 2019
- Decoding the building blocks of life: bit bio races toward a sustainable source of human cells - Proactive Investors UK - November 20th, 2019
- 1st SCD Trial Patient Shows CTX001 Gene Editing to be Safe, Effective - Sickle Cell Anemia News - November 20th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - BioSpace - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Arizona Daily Star - November 20th, 2019
- Maltese abroad: the best-selling author with roots in Gozo - Times of Malta - November 20th, 2019
- Early Results Are Positive for Experimental CRISPR Therapies - The Scientist - November 19th, 2019
- CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL - Lymphoma Hub - November 19th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - PRNewswire - November 19th, 2019
- Redding woman donates bone marrow, saves life of a father - FOX61 Hartford - November 16th, 2019
- Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) - Smarter Analyst - November 16th, 2019
- How 3D Printing Is Turning Each And Every Industry On Its Head - SafeHaven.com - November 16th, 2019
- BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders - Market Exclusive - November 16th, 2019
- Global Cell Expansion Market 2019 is predicted to reach an excellent valuation of by 2024 - Galus Australis - November 16th, 2019
- Stem Cell Assay Market is Growing Massively in Upcoming Year with Top Key Players like GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell... - November 15th, 2019
- Bone marrow transplant: What it is, uses, risks, and recovery - Medical News Today - November 15th, 2019
- The Demand of Mesenchymal Stem Cells Market Research Report 2019 Future Growth, Demand, Application, Trends, Vendor Landscape, Industry Insight,... - November 15th, 2019
- BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society - Yahoo Finance - November 14th, 2019
- BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire - November 14th, 2019
- BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting - Yahoo Finance - November 14th, 2019
- INDIA Indian doctor: Medical innovation should not try to replace the Creator - AsiaNews - November 14th, 2019
- iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting - Send2Press Newswire - November 14th, 2019
- Contrasting BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 14th, 2019
- Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell... - November 12th, 2019
- Army veteran to save woman with blood cancer through stem cell donation - Stoke-on-Trent Live - November 12th, 2019
- Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 12th, 2019
- Autolus Therapeutics Plc (AUTL) Q3 2019 Earnings Call Transcript - The Motley Fool - November 9th, 2019
- Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate... - October 29th, 2019
- Huntington's Marked by Inflammation and Changes in Brain's Striatum Before Symptoms, Study Finds - Huntington's Disease News - October 29th, 2019
- In 2030, Our Protein Will Come From a Laband We'll All Be Better Off For It - Singularity Hub - October 28th, 2019
- NASA plans to cut cost of space exploration by commercializing low-earth orbit - Digital Trends - October 27th, 2019
- BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference - BioSpace - October 27th, 2019
- Artificial Early Mouse Embryos Created In The Lab Using Stems Cells Rather Than Sperm Or Eggs - IFLScience - October 21st, 2019
- Healthcare Terms Are Out of Touch, Says Mom Advocate - Medscape - October 21st, 2019
- A stop-motion movie of the whole brain, starring new neurons - Spectrum - October 21st, 2019
- Humans evolved to think faster by slowing down brain development - New Scientist News - October 21st, 2019
- Stem Cell Banking Market was valued at $1986 million in 2016 - Markets Gazette - October 19th, 2019
- Republicans demand answers about government experiments with animals and fetal tissue - Washington Examiner - October 17th, 2019
- The Other Side of Stem Cell Research - The Tablet Catholic Newspaper - October 17th, 2019
- Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 17th, 2019
- SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly - October 17th, 2019
- Inherited Learning? It Happens, but How Is Uncertain - Quanta Magazine - October 17th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly - October 17th, 2019
- Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights - P&T... - October 7th, 2019
- New Tools in the Works to Probe Adult Human Neurogenesis - The Scientist - October 7th, 2019
- Follow the lead of Aston Villa players and become a blood stem cell donor - 7500 To Holte - October 7th, 2019
- Starving Cancer by Cutting Off Its Favorite Foods, Glucose and Glutamine - American Council on Science and Health - October 6th, 2019
- We're making tiny brains in the lab should we be worried for them? - CBC.ca - October 6th, 2019
- Female Scientist To Lead Advanced Cancer Research Project In Space - SheThePeople - October 6th, 2019
- Cancer cells to be tested in zero gravity on Chinese Space Station - E&T Magazine - October 4th, 2019
- Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic... - October 4th, 2019
- Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research - October 4th, 2019
- Genmab Announces U.S. FDA Approval of DARZALEX (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple... - September 27th, 2019
- The unexpected functional diversity of reactive astrocytes - Baylor College of Medicine News - September 27th, 2019
- Troy resident 'gets it done' with ground-breaking treatment - Troy Daily News - September 27th, 2019
- Stem Cell Assay Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2017 2025 - Herald Space - September 27th, 2019